What changed
$CSCO — AVOID 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ3 FY2026 (ends Apr) | reported May 13 | Rev $15.8B | EPS $1.06 vs $1.04 🟢 | Margin 25.0%
💡 Consensus expects AI networking to drive sustained double-digit revenue growth, but CSCO's core routing/switching faces secular headwinds and competitive pressure; the recent beat was small and may not be repeatable.
📉 Reward/risk: 1.7:1
🏢 Business Quality: 7/10
📊 Valuation: Rich — Trailing P/E 26.8x vs 15–20x historical range; EV/EBITDA likely >15x; FCF yield estimated below 3.5%, offering no margin of safety.
🔮 Catalyst: Next quarterly earnings (expected August 2026)
💰 Entry: $113.77, stop $125.0, target $95.0
⚖️ Avoid CSCO at current price; rich valuation with no obvious catalyst for further re-rating creates limited upside and asymmetric downside risk.